Canopus Biopharma In (CBIA) 0.1200 $CBIA
Ebola Viral Infections Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Dec 17, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zhmmv6/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Arno Therapeutics, Inc. - Canopus BioPharma Incorporated - Etubics Corporation - FIT Biotech Oy - Merck & Co., Inc. - Microbiotix, Inc. - Micropharm Limited - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxeal Holding SA - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/zh...bola_viral
UTHR: 110.21 (+0.97), MRK: 59.65 (+0.10)
Canopus BioPharma Inc. announces positive results from an In-Vitro live Ebola Virus study
PR Newswire Europe - Fri Dec 19, 8:00AM CST
Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.
Ebola Viral Infections Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Dec 17, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zhmmv6/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Arno Therapeutics, Inc. - Canopus BioPharma Incorporated - Etubics Corporation - FIT Biotech Oy - Merck & Co., Inc. - Microbiotix, Inc. - Micropharm Limited - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxeal Holding SA - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/zh...bola_viral
UTHR: 110.21 (+0.97), MRK: 59.65 (+0.10)
Canopus BioPharma Inc. announces positive results from an In-Vitro live Ebola Virus study
PR Newswire Europe - Fri Dec 19, 8:00AM CST
Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition.
